• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Gelesis spikes IPO, raises $32m instead

Gelesis spikes IPO, raises $32m instead

December 22, 2015 By Brad Perriello

GelesisA day after officially spiking its plans for an initial public offering, Gelesis said it raised another $31.5 million for its anti-obesity pill.

The Gelesis100 is designed to induce a feeling of satiety and improve glycemic control, using a super-absorbent hydrogelthat expands in the stomach after being swallowed. Boston-based Gelesis tabled the $56 million IPO in May due to turbulence in the U.S. biotech market, and officially withdrew the flotation Dec. 17 “due to market conditions,” according to a regulatory filing.

A day later Gelesis announced the $31.5 million growth round, with participation from new backer Cormorant Asset Management and existing investors Invesco Asset Management, PureTech and the Priztker/Vlock Family Office. Gelesis, which raised a $22 million funding round in March, said the latest funding brings its total raise to more than $90 million.

The proceeds are earmarked for the completion of a 6-month pivotal trial for Gelesis100, with top-line data expected in the 1st half of 2017, Gelesis said.

“We appreciate the support of Gelesis’ new and existing investors as we aim to bring novel therapies to the market to address the obesity and diabetes epidemics,” co-founder & CEO Yishai Zohar said in prepared remarks. “We look forward to completing our U.S. pivotal trial of Gelesis100 and, if approved, we believe it has the potential to address the significant unmet need for an orally dosed, safe and efficacious therapy to induce weight loss and improve glycemic control.”

A 2nd product, Gelesis200, is under development. Gelesis said part of the new funding will go to comple 1st-in-human studies for that device, “with anticipated read-out of a 3-month proof-of-concept study expected in the 2nd half of 2016,” the company said.

Filed Under: Clinical Trials, Funding Roundup, Weight loss Tagged With: Gelesis Inc.

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy